Intrasense combines its technological expertise with the clinical expertise of the Compagnie de Télémédecine (CTM Groupe) by deploying to all of the group's radiotherapy specialists the new scanner reading protocol dedicated to COVID-19.

The company announces the release and immediate availability of a specific scanner reading protocol dedicated to COVID-19.

Intrasense™ announces its 2019 annual results.

Artificial intelligence will be highlighted on Intrasense™ booth (#6956). The new version of Myrian® platform enabling artificial intelligence to truly be embedded into the daily workflow and clinical routine.

All innovations will be presented at JFR 2019 on the Intrasense ™ booth (# 213A). The new version of Myrian® as well as the XP-Mammo application will be display.

This new version of Myrian® brings many clinical innovations and a new application.

Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.

Myrian® XP-Mammo, can now be commercialized on the European market.

Myrian® XP Prostate, the new reference tool for worldwide prostate experts.

Elonav, a brand-new application dedicated to specifical needs of neurosurgeons.